JEANNA WELBORN, M.D.; FREDERICK J. MEYERS, M.D.; LOIS F. O'GRADY, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Hutchinson and associates (1) report a salt wasting nephropathy in 10% of patients with lung cancer treated with cisplatinum. We saw a similar occurrence in 1 of 25 patients on a phase-I trial using carboplatinum in refractory patients who had relapses with acute leukemia (2).
A 78-year-old man with acute nonlymphocytic leukemia had fever and volume depletion with orthostatic hypotension. His only medication was Tylenol. Admission sodium level was 128 mmol/L; potassium, 5.0 mmol/L; CO2, 21 mmol/L; and creatinine, 2.3 mg/dL. The urine sodium level was 19 mmol/L; urine osmolality, 370 mmol/kg; fractional excretion of sodium, 0.05%;
WELBORN J, MEYERS FJ, O'GRADY LF. Renal Salt Wasting and Carboplatinum. Ann Intern Med. 1988;108:640. doi: https://doi.org/10.7326/0003-4819-108-4-640_1
Download citation file:
Published: Ann Intern Med. 1988;108(4):640.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use